Product Description
Mechanisms of Action: PI3K Inhibitor,mTOR
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SpringWorks Therapeutics
Company Location: STAMFORD CT 06902
Company CEO: Saqib Islam
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Glioma|Neurofibroma, Plexiform|Neurofibromatoses|Neurofibromatosis 1|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SJ901 | P2 |
Recruiting |
Glioma |
2031-06-01 |
|
| MEKRAF-AST-101 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-10-31 |
57% |
| MEKRAF-AST-101 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-10-31 |
57% |
| BGB-283/PD-0325901-AU-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-09-30 |
50% |
| BGB-283/PD-0325901-AU-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-09-30 |
50% |
| ReNeu | P2 |
Active, not recruiting |
Neurofibroma, Plexiform|Neurofibromatosis 1|Neurofibromatoses |
2023-09-20 |
57% |